Hepatitis delta virus infection prevalence, diagnosis and treatment in the Middle East: A scoping review

Jeffrey V Lazarus 1 2, Ahmad Al-Rifai 3, Faisal M Sanai 4, Abdullah Saeed Alghamdi 5, Ala I Sharara 6, Motaz Fathy Saad 7, Lena van Selm 1, Saleh A Alqahtani 8 9

Affiliations

11 June 2022

-

doi: 10.1111/liv.15338

Abstract

Hepatitis D virus (HDV) infection is a global public health concern, especially because of its unique existence in the presence of hepatitis B virus infection. HDV infection is estimated to affect 12 million people globally. Having a clearer understanding of its prevalence in all regions of the world is essential for helping direct preventive and early interventional treatment. This mini-review assessed the literature over the last 10 years to determine the prevalence, diagnostic means and treatment guidelines available for HDV in the Middle East. The search found limited data available in 21 articles, of which 18 were studies focused on Iran. Prevalence rates ranged dramatically among the countries, and none of the 12 countries included in the search had specific HDV guidelines. This review highlights the urgent need for more precise data for the Middle East region to help establish early diagnosis and treatment options for HDV.

Keywords: Middle East; guidelines; hepatitis D virus; prevalence; treatment.

Similar articles

The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis.

Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, Hutin Y, Geretti AM.J Hepatol. 2020 Sep;73(3):523-532. doi: 10.1016/j.jhep.2020.04.008. Epub 2020 Apr 23.PMID: 32335166 Free PMC article.

Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.

Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.PMID: 36321557 Free PMC article.

Prevalence of hepatitis d virus infection among patients with chronic hepatitis B attending birjand hepatitis clinic (East of iran) in 2012.

Ziaee M, Azarkar G.Hepat Mon. 2013 Aug 25;13(8):e11168. doi: 10.5812/hepatmon.11168. eCollection 2013.PMID: 24171009 Free PMC article.

Underestimated Prevalence of HIV, Hepatitis B Virus (HBV), and Hepatitis D Virus (HDV) Triple Infection Globally: Systematic Review and Meta-analysis.

Chen S, Ren F, Huang X, Xu L, Gao Y, Zhang X, Cao Y, Fan Z, Tian Y, Liu M.JMIR Public Health Surveill. 2022 Nov 29;8(11):e37016. doi: 10.2196/37016.PMID: 36445732 Free PMC article. Review.

Hepatitis Delta Virus Epidemiology in the Industrialized World.

Toy M, Ahishali E, Yurdaydın C.AIDS Rev. 2020 Oct 26;22(4):203-212. doi: 10.24875/AIDSRev.20000056.PMID: 33104688 Review.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. Lee AU, Lee C. Hepatitis D review: challenges for the resource-poor setting. Viruses. 2021;13(10):1912. doi:10.3390/V13101912
  2.  
    1. Stockdale AJ, Kreuels B, Henrion MYR, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020;73(3):523-532. doi:10.1016/J.JHEP.2020.04.008
  3.  
    1. Miao Z, Zhang S, Ou X, et al. Estimating the global prevalence, disease progression, and clinical outcome of Hepatitis Delta virus infection. J Infect Dis. 2020;221(10):1677-1687. doi:10.1093/infdis/jiz633
  4.  
    1. WHO. Hepatitis D. https://www.who.int/news-room/fact-sheets/detail/hepatitis-d. Accessed December 17, 2021.
  5.  
    1. Yurdaydin C, Toy M. Hepatitis Delta virus infection: a large burden after all? J Infect Dis. 2020;221(10):1573-1575. doi:10.1093/INFDIS/JIZ634
  6.  
    1. Masetti C, Aghemo A. Bulevirtide for treatment of patients with HDV infection and compensated cirrhosis: a (huge?) step in the right direction. Liver Int. 2021;41:1441-1442. doi:10.1111/liv.14967
  7.  
    1. Sandmann L, Cornberg M. Experimental drugs for the treatment of hepatitis D. J Exp Pharmacol. 2021;13:461. doi:10.2147/JEP.S235550
  8.  
    1. Asselah T, Loureiro D, Le Gal F, et al. Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life. Liver Int. 2021;41(7):1509-1517. doi:10.1111/liv.14950
  9.  
    1. Gokcan H, Idilman R. Hepatitis D infection in Asia: a perspective from an endemic region. Clin Liver Dis. 2021;18(1):26. doi:10.1002/CLD.1106
  10.  
    1. Vlachogiannakos J, Papatheodoridis GV. New epidemiology of hepatitis delta. Liver Int. 2020;40:48-53. doi:10.1111/liv.14357
  11.  
    1. Terrault NA, Lok ASF, Mcmahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-1599. doi:10.1002/hep.29800
  12.  
    1. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2017;67(2):370-398.
  13.  
    1. Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;2072(10):1-98. doi:10.1007/s12072-015-9675-4
  14.  
    1. WHO. Regional action plan for the implementation of the global health sector strategy on viral hepatitis 2017-2021. Published Online 2017.
  15.  
    1. Rizzetto M, Hamid S, Negro F. The changing context of hepatitis D. J Hepatol. 2021;74(5):1200-1211. doi:10.1016/J.JHEP.2021.01.014
  16.  
    1. Hayashi T, Takeshita Y, Hutin YJ-F, et al. The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response? Arch. Public Health. 2021;79(1):180. doi:10.1186/s13690-021-00693-2
  17.  
    1. Alavian SM, Tabatabaei SV, Ghadimi T, et al. Seroprevalence of hepatitis B virus infection and its risk factors in the west of Iran: a population-based study. Int J Prev Med. 2012;3(11):770.
  18.  
    1. Javanmard D, Alavian SM, Abedi F, Hasan Namaei M, Asghari A, Ziaee M. High prevalence of hepatitis B virus infection in the village of Esfandiar in South Khorasan Province. Iran. 2018;18(8):65473. doi:10.5812/hepatmon.65473
  19.  
    1. Sharifzadeh G, Namaei MH, Ebrahimzadeh A, et al. Prevalence of hepatitis D virus infection and associated factors among HBsAg-positive patients in Birjand, Iran, 2012-2014. Hepat Mon. 2017;17(5):e42866. doi:10.5812/hepatmon.42866
  20.  
    1. Ghadir M-R, Belbasi M, Heidari A, et al. Prevalence of hepatitis D virus infection among hepatitis B virus infected patients in Qom Province, Center of Iran. Hepat Mon. 2012;12(3):205. doi:10.5812/HEPATMON.847
  21.  
    1. Alavian SM, Tabatabaei SV, Nourizad S, Mansouri F, Khademi N, Kafi-Abad A. Seroepidemiology of HBV infection in Kermanshah-west of Iran; a population based study. Jundishapur J Microbiol. 2012;5(4):564-573. doi:10.5812/jjm.4156
  22.  
    1. Salehi M, Alavian SM, Tabatabaei SV, et al. Seroepidemiology of HBV infection in south-east of Iran; a population based study. Iran Red Crescent Med J. 2012;14(5):283.
  23.  
    1. Behzadi MA, Leyva-Grado VH, Namayandeh M, et al. Seroprevalence of viral hepatitis a, B, C, D and E viruses in the Hormozgan province southern Iran. BMC Infect Dis. 2019;19(1):1027. doi:10.1186/s12879-019-4661-4
  24.  
    1. Sayad B, Naderi Y, Alavian SM, et al. Hepatitis D virus infection in Kermanshah, west of Iran: seroprevalence and viremic infections. Gastroenterol Hepatol from Bed to Bench. 2018;11(2):145-152.
  25.  
    1. Attaran MS, Sharifi Z, Hosseini SM, Samei S, Ataee Z. Prevalence of hepatitis B and hepatitis D coinfection in asymptomatic blood donors in Iran. APMIS. 2014;122(3):243-247. doi:10.1111/APM.12137
  26.  
    1. Pouri AA, Ghojazadeh M, Baiaz B, Hamzavi FS, Pourasghari B, Somi MH. Prevalence of hepatitis D virus among HBsAg-positive individuals, 2015-2016: azar cohort study. Health Promot Perspect. 2020;10(1):38-42. doi:10.15171/hpp.2020.07
  27.  
    1. Keshvari M, Alavian SM, Aghaee B, et al. Seroepidemiology and clinical features of hepatitis delta among HBsAg carriers: a study from hepatitis clinic of Iranian blood transfusion organization. Transfus Med. 2014;24(6):411-417. doi:10.1111/TME.12163
  28.  
    1. Ziaee M, Azarkar G. Prevalence of hepatitis D virus infection among patients with chronic hepatitis B attending Birjand hepatitis clinic (east of Iran) in 2012. Hepat Mon. 2013;13(8):11168. doi:10.5812/HEPATMON.11168
  29.  
    1. Khazaee T, Ebrahimzadeh A, Govaresh EM, 2015. Assessment of prevalence and determine infections of hepatitis C and hepatitis D in patients with chronic hepatitis B. govaresh.org. Published online 2015. http://www.govaresh.org/index.php/dd/article/view/1451. Accessed April 5, 2022.
  30.  
    1. Tahaei SME, Mohebbi SR, Azimzadeh P, et al. Prevalence of hepatitis D virus in hepatitis B virus infected patients referred to Taleghani hospital, Tehran, Iran. Gastroenterol Hepatol Bed Bench. 2014;7(3):144.
  31.  
    1. Alavian SM, Imanieh MH, Imanieh MH. Predictive factors in the incidence of cirrhosis in chronic hepatitis B virus infections. Hepat Mon. 2016;16(5):34790. doi:10.5812/HEPATMON.34790
  32.  
    1. Pournik O, Alavian SM, Ghalichi L, Hajibeigi B, Razavi AR, Eslami S. Lower intrafamilial transmission rate of hepatitis B in patients with hepatitis D coinfection: a data-mining approach. Hepat Mon. 2013;13(5):e7652. doi:10.5812/HEPATMON.7652
  33.  
    1. Bakhshipour A, Mashhadi M, Mohammadi M, Nezam SK. Seroprevalence and risk factors of hepatitis delta virus in chronic hepatitis B virus infection in Zahedan. Acta Med Iran. 2013;51(4):260-264. http://acta.tums.ac.ir/index.php/acta/article/view/4451. Accessed April 1, 2022
  34.  
    1. Sharifan P, Amoueian S. Histological and serological epidemiology of Hepatitis Delta virus coinfection among patients with chronic active hepatitis B virus in Razavi Khorasan Province, northeastern Iran. Iran J Public Health. 2018;47(12):1906.
  35.  
    1. Jamjoom GA, El-Daly MM, Azhar EI, et al. Prevalence and molecular characterization of hepatitis D virus in Saudi Arabia: a single-center study. Saudi J Gastroenterol. 2017;23(3):176-182. doi:10.4103/SJG.SJG_515_16
  36.  
    1. Hussein NR, Rasheed ZA, Taha AA, Shaikhow SK. The prevalence of hepatitis D virus infection amongst patients with chronic active hepatitis B virus infection in Duhok governorate. Int J Pure Appl Sci Technol. 2015;28(1):1-7. www.ijopaasat.in. Accessed October 20, 2021
  37.  
    1. Al-Nabehi B, Al-Shamahy H, Saeed W, et al. Sero-molecular epidemiology and risk factors of viral hepatitis in urban Yemen. Int J Virol. 2015;11(3):133-138. doi:10.3923/ijv.2015.133.138
  38.  
    1. Qaseer B. Jordan Viral Hepatitis B & C 2016. The Hashemite Kingdom of Jordan Ministry of Health. Published 2016. https://www.researchgate.net/publication/308790306_Jordan_viral_hepatiti.... Accessed October 26, 2021.
  39.  
    1. Abaalkhail FA, Al-Hamoudi WK, Khathlan A, et al. SASLT practice guidelines for the management of hepatitis B virus - an update. Saudi J Gastroenterol. 2021;27(3):115-126. doi:10.4103/SJG.SJG_539_20
  40.  
    1. Abaalkhail F, Elsiesy H, AlOmair A, et al. SASLT practice guidelines for the management of Hepatitis B Virus. Saudi J Gastroenterol. 2014;20(1):5-25. doi:10.4103/1319-3767.126311
  41.  
    1. Al Zaabi M, Al Quraishi H, Al Rifai A, et al. Hepatitis B care pathway in the United Arab Emirates: current situation, gaps, and actions. 10.33590/emjhepatol/19-00061
  42.  
    1. Hasan F, Bahbahani A, Askar H, et al. Hepatitis B prevention and care pathway in Kuwait: assessing the current situation, identifying gaps and recommending actions. Published Online 2019. www.ncbi.nlm.nih.gov/pubmed/. Accessed October 25, 2021.
  43.  
    1. Lebanese Guidelines for the Treatment of HBV Infection. Lebanese Society of Gastroenterology. https://lsge.org/local_guidelines. Accessed October 26, 2021.
  44.  
    1. Bashour H, Muhjazi G. Hepatitis B and C in the Syrian Arab Republic: a review. East Mediterr Health J. 2016;22(4):267-273. www.moh. Accessed October 26, 2021
  45.  
    1. Makhlouf NA, Morsy KH, Mahmoud AA. Hepatitis D virus infection among hepatitis B virus surface antigen positive individuals in upper Egypt: prevalence and clinical features. J Infect Public Health. 2019;12(3):350-356. doi:10.1016/J.JIPH.2018.12.001
  46.  
    1. Toukan AU, Abu-El-Rub OA, Abu-Laban SA, et al. The epidemiology and clinical outcome of hepatitis D virus (delta) infection in Jordan. Hepatology. 1987;7(6):1340-1345. doi:10.1002/HEP.1840070627
  47.  
    1. Al-Kandari S, Nordenfelt E, Al-Nakib B, Hansson BG, Ljunggren K, Al-Nakib W. Hepatitis delta virus infection in acute hepatitis in Kuwait. Scand J Infect Dis. 1988;20(1):15-19. doi:10.3109/00365548809117212
  48.  
    1. Guneid AME, Gunaid AA, O'Neill AM, Zureikat NI, Coleman JC, Murray-Lyon IM. Prevalence of hepatitis B, C, and D virus markers in yemeni patients with chronic liver disease. J Med Virol. 1993;40(4):330-333. doi:10.1002/JMV.1890400413
  49.  
    1. Al-Dhahry SHS, Aghanashinikar N, Al-Marhuby HA, Buhl MR, Daar AS, Al-Hasani MK. Hepatitis B, Delta and human immunodeficiency virus infections among Omani patients with renal diseases: a seroprevalence study. Ann Saudi Med. 1994;14(4):312-315.
  50.  
    1. Ramia S, El-zaatari M, Sharara AI, Ramlawi F, Farhat B. Current prevalence of hepatitis delta virus (HDV) infection and the range of HDV genotypes in Lebanon. Epidemiol Infect. 2007;135(6):959-962. doi:10.1017/S0950268806007643
  51.  
    1. WHO. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Published July 15, 2021. https://www.who.int/publications/i/item/9789240027077. Accessed November 18, 2021.
  52.  
    1. Esmat G. A review of chronic hepatitis B epidemiology and management issues in selected countries in the Middle East. J Viral Hepat. 2012;19(1):9-22. doi:10.1111/J.1365-2893.2011.01511.X
  53.  
    1. Sanai FM, Alghamdi M, Dugan E, et al. A tool to measure the economic impact of hepatitis B elimination: a case study in Saudi Arabia. J Infect Public Health. 2020;13(11):1715-1723. doi:10.1016/J.JIPH.2020.09.004
  54.  
    1. Pattyn J, Hendrickx G, Vorsters A, Van Damme P. Hepatitis B vaccines. J Infect Dis. 2021;224(Supplement_4):S343-S351. doi:10.1093/INFDIS/JIAA668
  55.  
    1. Razavi-Shearer D, Gamkrelidze I, Nguyen MH, et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383-403. doi:10.1016/S2468-1253(18)30056-6
  56.  
    1. Niro GA, Ferro A, Cicerchia F, Brascugli I, Durazzo M. Hepatitis delta virus: from infection to new therapeutic strategies. World J Gastroenterol. 2021;27(24):3530. doi:10.3748/WJG.V27.I24.3530
  57.  
    1. Yurdaydin C, Abbas Z, Buti M, et al. Treating chronic hepatitis delta: the need for surrogate markers of treatment efficacy. J Hepatol. 2019;70(5):1008-1015. doi:10.1016/j.jhep.2018.12.022
  58.  
    1. WHO. Global health sector strategy on viral hepatitis 2016-2021. Towards Ending Viral Hepatitis Published online 2016. https://apps.who.int/iris/bitstream/handle/10665/246177/WHO?sequence=1. Accessed November 4, 2021.

Page Navigation